Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

Presentation TVT 2023

Position 2: The Trial Was Obviously Negative: Stop Wasting Money!

Presenter: David Cohen

June 09, 2023

Presentation TVT 2023

Highlighting the Importance and Pitfalls in Interpreting Patient Reported Outcomes

Presenter: David Cohen

June 08, 2023

Presentation TVT 2022

Novel Digital Approaches to Aortic Valve Disease Screening: Introduction to the PREVUE VALVE Study

Presenter: David J. Cohen

June 09, 2022

Presentation TVT 2022

Flash Proposal: A Novel Bicuspid TAVR Trial in the Modern Era

Presenter: David Cohen

June 08, 2022

Presentation TVT 2021

TV Trials and Economics: What Is a TV Life Worth?

Presenter: David Cohen

July 22, 2021

Presentation TVT 2021

Clinical Trial Considerations for Bicuspid Aortic Valve for Disease: What Should the Next Study Look Like?

Presenter: David Cohen

July 20, 2021

Presentation TVT 2017

Is the Current Practice of Watchful Waiting in Severe AS a Viable Strategy in the Future?

Presenter: David J. Cohen, Jeffrey J. Popma, Robert O. Bonow

June 16, 2017

Presentation TVT 2017

Rationale and Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Philippe Généreux

June 16, 2017

Presentation TVT 2017

Rationale and Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

Presenter: David J. Cohen, Jeffrey J. Popma, Nicolas M. Van Mieghem

June 16, 2017

Presentation TVT 2017

A Practical Clinical Algorithm for Correctly Diagnosing and Managing Patients With Low Flow Aortic Stenosis

Presenter: David J. Cohen, Jeffrey J. Popma, Howard C. Herrmann

June 16, 2017

Presentation TVT 2017

A Model of TAVR (vs SAVR) Case Selection, Based Solely on Clinical and Anatomic Factors

Presenter: David J. Cohen, Jeffrey J. Popma, Martin B. Leon

June 16, 2017

Presentation TVT 2017

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

Presenter: David J. Cohen, Jeffrey J. Popma, Vinod H. Thourani

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette III: Subset Analysis of Strokes

Presenter: David J. Cohen, Jeffrey J. Popma, A. Pieter Kappetein

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Michael J. Reardon

June 16, 2017

Presentation TVT 2017

Prevalence of Amyloid in Patients Undergoing TAVR: Low-Flow Phenotype and Echocardiographic Predictors

Presenter: David J. Cohen, Mark J. Russo, Adam Castano

June 16, 2017

Presentation TVT 2017

TAVR to Treat Aortic Regurgitation in LVAD Patients Rationale and Case Examples

Presenter: David J. Cohen, Mark J. Russo, Nir Uriel

June 16, 2017

Presentation TVT 2017

Emergent TAVR for AS Patients With Intractable Heart Failure: Feasibility and Early Clinical Results

Presenter: David J. Cohen, Mark J. Russo, Ran Kornowski

June 16, 2017

Presentation TVT 2017

Who Shouldnt Undergo TAVR? Can We Identify Non-responders?

Presenter: David J. Cohen, Mark J. Russo, Suzanne V. Arnold

June 16, 2017

Advertisement

Position 2: The Trial Was Obviously Negative: Stop Wasting Money!

Highlighting the Importance and Pitfalls in Interpreting Patient Reported Outcomes

Novel Digital Approaches to Aortic Valve Disease Screening: Introduction to the PREVUE VALVE Study

Flash Proposal: A Novel Bicuspid TAVR Trial in the Modern Era

TV Trials and Economics: What Is a TV Life Worth?

Clinical Trial Considerations for Bicuspid Aortic Valve for Disease: What Should the Next Study Look Like?

Is the Current Practice of Watchful Waiting in Severe AS a Viable Strategy in the Future?

Rationale and Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Rationale and Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

A Practical Clinical Algorithm for Correctly Diagnosing and Managing Patients With Low Flow Aortic Stenosis

A Model of TAVR (vs SAVR) Case Selection, Based Solely on Clinical and Anatomic Factors

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

SURTAVI Vignette III: Subset Analysis of Strokes

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Prevalence of Amyloid in Patients Undergoing TAVR: Low-Flow Phenotype and Echocardiographic Predictors

TAVR to Treat Aortic Regurgitation in LVAD Patients Rationale and Case Examples

Emergent TAVR for AS Patients With Intractable Heart Failure: Feasibility and Early Clinical Results

Who Shouldnt Undergo TAVR? Can We Identify Non-responders?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content